Cargando…

Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension

Pulmonary hypertension is one of the difficult situations to treat. Complex pathophysiology, association of the multiple comorbidities make clinical scenario challenging. Recently it is being shown that patients who had recovered from coronavirus disease infection, are at risk of developing pulmonar...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajra, Adrija, Safiriyu, Israel, Balasubramanian, Prasanth, Gupta, Rahul, Chowdhury, Selia, Prasad, Abhishek J., Kumar, Akshay, Kumar, Deepak, Khan, Baseer, Bilberry, Roberta S.F., Sarkar, Ankit, Malik, Paras, Aronow, Wilbert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171713/
https://www.ncbi.nlm.nih.gov/pubmed/35500734
http://dx.doi.org/10.1016/j.cpcardiol.2022.101236
_version_ 1784721726947459072
author Hajra, Adrija
Safiriyu, Israel
Balasubramanian, Prasanth
Gupta, Rahul
Chowdhury, Selia
Prasad, Abhishek J.
Kumar, Akshay
Kumar, Deepak
Khan, Baseer
Bilberry, Roberta S.F.
Sarkar, Ankit
Malik, Paras
Aronow, Wilbert S.
author_facet Hajra, Adrija
Safiriyu, Israel
Balasubramanian, Prasanth
Gupta, Rahul
Chowdhury, Selia
Prasad, Abhishek J.
Kumar, Akshay
Kumar, Deepak
Khan, Baseer
Bilberry, Roberta S.F.
Sarkar, Ankit
Malik, Paras
Aronow, Wilbert S.
author_sort Hajra, Adrija
collection PubMed
description Pulmonary hypertension is one of the difficult situations to treat. Complex pathophysiology, association of the multiple comorbidities make clinical scenario challenging. Recently it is being shown that patients who had recovered from coronavirus disease infection, are at risk of developing pulmonary hypertension. Studies on animals have been going on to find out newer treatment options. There are recent advancements in the treatment of pulmonary hypertension. Role of anticoagulation, recombinant fusion proteins, stem cell therapy are emerging as therapeutic options for affected patients. SGLT2 inhibitors have potential to have beneficial effects on pulmonary hypertension. Apart from the medical managements, advanced interventions are also getting popular. In this review article, the authors have discussed pathophysiology, recent advancement of treatments including coronavirus disease patients, and future aspect of managing pulmonary hypertension. We have highlighted treatment options for patients with sleep apnea, interstitial lung disease to discuss the challenges and possible options to manage those patients.
format Online
Article
Text
id pubmed-9171713
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-91717132022-06-07 Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension Hajra, Adrija Safiriyu, Israel Balasubramanian, Prasanth Gupta, Rahul Chowdhury, Selia Prasad, Abhishek J. Kumar, Akshay Kumar, Deepak Khan, Baseer Bilberry, Roberta S.F. Sarkar, Ankit Malik, Paras Aronow, Wilbert S. Curr Probl Cardiol Article Pulmonary hypertension is one of the difficult situations to treat. Complex pathophysiology, association of the multiple comorbidities make clinical scenario challenging. Recently it is being shown that patients who had recovered from coronavirus disease infection, are at risk of developing pulmonary hypertension. Studies on animals have been going on to find out newer treatment options. There are recent advancements in the treatment of pulmonary hypertension. Role of anticoagulation, recombinant fusion proteins, stem cell therapy are emerging as therapeutic options for affected patients. SGLT2 inhibitors have potential to have beneficial effects on pulmonary hypertension. Apart from the medical managements, advanced interventions are also getting popular. In this review article, the authors have discussed pathophysiology, recent advancement of treatments including coronavirus disease patients, and future aspect of managing pulmonary hypertension. We have highlighted treatment options for patients with sleep apnea, interstitial lung disease to discuss the challenges and possible options to manage those patients. Elsevier 2023-08 2022-04-29 /pmc/articles/PMC9171713/ /pubmed/35500734 http://dx.doi.org/10.1016/j.cpcardiol.2022.101236 Text en . Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hajra, Adrija
Safiriyu, Israel
Balasubramanian, Prasanth
Gupta, Rahul
Chowdhury, Selia
Prasad, Abhishek J.
Kumar, Akshay
Kumar, Deepak
Khan, Baseer
Bilberry, Roberta S.F.
Sarkar, Ankit
Malik, Paras
Aronow, Wilbert S.
Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension
title Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension
title_full Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension
title_fullStr Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension
title_full_unstemmed Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension
title_short Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension
title_sort recent advances and future prospects of treatment of pulmonary hypertension
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171713/
https://www.ncbi.nlm.nih.gov/pubmed/35500734
http://dx.doi.org/10.1016/j.cpcardiol.2022.101236
work_keys_str_mv AT hajraadrija recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT safiriyuisrael recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT balasubramanianprasanth recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT guptarahul recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT chowdhuryselia recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT prasadabhishekj recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT kumarakshay recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT kumardeepak recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT khanbaseer recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT bilberryrobertasf recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT sarkarankit recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT malikparas recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension
AT aronowwilberts recentadvancesandfutureprospectsoftreatmentofpulmonaryhypertension